Ankündigung • Apr 10
Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 1.850332 million. Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 1.850332 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 30,838,873
Price\Range: AUD 0.06
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing New Risk • Feb 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 12% per year over the past 5 years. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (AU$1.9m revenue, or US$1.3m). Market cap is less than US$100m (AU$23.1m market cap, or US$15.3m). Ankündigung • Nov 22
Nuheara Limited Announces the Retirement of David Cannington as Non-Executive Director Nuheara Limited announced that Non-executive Director and co-founder Mr. David Cannington has announced his decision to retire from the Nuheara Board of Directors. As a co-founder of the company and having previously stepped down from executive duties in March 2022, David now concludes his service on the Board. Ankündigung • Nov 09
Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 3.929624 million. Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 3.929624 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 3,846,154
Price\Range: AUD 0.13
Discount Per Security: AUD 0.0039
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 19,458,649
Price\Range: AUD 0.13
Discount Per Security: AUD 0.0039
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 6,923,077
Price\Range: AUD 0.13
Discount Per Security: AUD 0.0039
Transaction Features: Rights Offering New Risk • Oct 19
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 62% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$10m free cash flow). Earnings have declined by 12% per year over the past 5 years. Shareholders have been substantially diluted in the past year (62% increase in shares outstanding). Minor Risks Revenue is less than US$5m (AU$1.9m revenue, or US$1.2m). Market cap is less than US$100m (AU$30.1m market cap, or US$19.0m). Reported Earnings • Oct 03
Full year 2023 earnings released: AU$0.084 loss per share (vs AU$0.16 loss in FY 2022) Full year 2023 results: AU$0.084 loss per share (improved from AU$0.16 loss in FY 2022). Revenue: AU$1.93m (down 50% from FY 2022). Net loss: AU$12.6m (loss narrowed 15% from FY 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings. Ankündigung • Sep 15
Nuheara Limited, Annual General Meeting, Nov 22, 2023 Nuheara Limited, Annual General Meeting, Nov 22, 2023, at 09:00 W. Australia Standard Time. Location: Anzac Club, 28 St Georges Terrace, Perth WA Australia Reported Earnings • Aug 30
Full year 2023 earnings released: AU$0.074 loss per share (vs AU$0.16 loss in FY 2022) Full year 2023 results: AU$0.074 loss per share (improved from AU$0.16 loss in FY 2022). Revenue: AU$1.93m (down 50% from FY 2022). Net loss: AU$11.2m (loss narrowed 22% from FY 2022). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings. Ankündigung • Jul 18
Nuheara Limited Announces Appointment of Catherine Morgan as Head of Compliance, Regulatory and Legal Nuheara Limited announced the key Executive appointment of Catherine Morgan as the Head of Compliance, Regulatory and Legal. This appointment completes Nuheara's global restructure announced 28 April 2023 and cements the Company's transformation over the past two years into a medical device manufacturer of world-first US FDA- cleared Over The Counter (OTC) Hearing Aids. Catherine joins the Nuheara C-suite with over +20 years of experience in the hearing industry, bringing a deep understanding of the hearing healthcare, medical device industry, global regulatory requirements, and quality standards. In this new role Catherine will be responsible for driving regulatory strategies, ensuring adherence to global regulations and standards, and driving continuous improvement initiatives within quality management systems. They will collaborate closely with cross-functional teams to streamline regulatory submissions, enhance product quality, and foster a culture of continuous improvement in all aspects of regulatory and quality operations. Prior to joining Nuheara, Catherine held senior leadership positions at the National Acoustic Laboratories and more than 14 years with Cochlear Ltd. Catherine has a proven track record of successfully navigating complex regulatory landscapes and implementing strong clinical quality management processes and while fostering a culture of regulatory compliance and quality excellence within the hearing market. Ankündigung • Jun 07
Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 4.4 million. Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 4.4 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 24,275,862
Price\Range: AUD 0.145
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 6,068,966
Price\Range: AUD 0.145
Transaction Features: Subsequent Direct Listing Reported Earnings • Mar 09
First half 2023 earnings released: AU$0.048 loss per share (vs AU$0.065 loss in 1H 2022) First half 2023 results: AU$0.048 loss per share. Revenue: AU$765.6k (down 74% from 1H 2022). Net loss: AU$6.46m (loss widened 7.5% from 1H 2022). Board Change • Feb 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Independent Non-Executive Chairman Chery Edwardes was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Ankündigung • Jan 04
Nuheara Announces Commercial Availability of HP Hearing PRO OTC Hearing Aid Nuheara announced the commercial availability of its HP Hearing PRO. Consumers can now pre-order the HP Hearing PRO self-fitting, air-conduction, OTC hearing soon be able to purchase the product from any retailer carrying the product including Best Buy and Crutchfield. Nuheara's HP Hearing PRO is the first product cleared through the FDA's 510(k) process for both 874.3325 self-fitting and the 800.30 OTC hearing aid classifications under a new product classification code "QUH". HP Hearing PRO is the first FDA cleared self-fitting OTC hearing aid with Hybrid Active Noise Cancellation. The innovative Ear ID(TM) software-in-medical-device and earbud form factor sets the HP Hearing PRO apart from other devices on the market . The HP Hearing PRO self-fitting OTC hearing aids look nothing like a traditional hearing aid. The HP Hearing PRO self- fitting OTC hearing aid brings together superb medical-grade hearing aid technology with the highly desired features of wireless earbuds into a multifunctional device. Users can enjoy clinically-proven natural sound quality. The HP Hearing PRO provides a lifestyle-friendly hearing aid experience with support for situational use and clinically-proven 30% improved hearing using the Focus directionality feature, adjusted to the user's preferences with a tap of the HP Hearing app. Orders can now be placed from retailers and ecommerce partners throughout the US. The recommended retail price for a pair of HP Hearing PRO hearing aids along with an on-the-go charging case is USD 699.00. Product is expected to ship to customers before the end of calendar Quarter 1, 2023. Built to medical-device standards and meeting all FDA requirements for safety and efficacy, the HP Hearing PRO features Ear ID(TM) self-fitting software and technology powered by Nuheara. The HP Hearing PRO self-fitting OTC hearing aid has been clinically proven to be substantially equivalent to a professionally fit hearing aid. The proprietary Ear ID software tests the wearer's individual hearing thresholds from low frequency to high frequency in each ear, then automatically programs the HP Hearing PRO hearing aids for each ear. This ability for the consumer to self-fit through the HP Hearing application, for iOS and Android platform mobile devices, allows a quick and easy acclimation experience for the consumer. The entire experience takes about 10-15 minutes from unboxing through customization of the user's personalized profile to accommodate their perceived mild-to-moderate hearing loss. In addition to the HP Hearing PRO's capabilities as an OTC hearing aid, this innovative product streams media and phone calls via Bluetooth(R). The Active Noise Cancellation minimizes background noise for an immersive sound experience during phone calls or when streaming music. Additional features include: Hearing app for iOS and Android; Rechargeable built-in Li-ion batteries; Medical-grade USB-C charge case; Battery life is up to 8 hours hearing aid processing per full charge per hearing aid; Clinically-proven natural sound quality. Most importantly, the HP Hearing PRO has been clinically validated through research cometed by the National Acoustic c Laboratories to provide a 30% speech understanding improvement in the presence of noise using the directional microphone feature called Focus. This is a huge benefit for consumers in restaurants or social situations where background noise makes understanding speech difficult. Now, at the touch of the HP Hearing app, a wearer can switch the directional microphone settings to Focus on sounds towards their front, quickly allowing for immediate improvement in speech understanding. Reported Earnings • Oct 08
Full year 2022 earnings released: AU$0.16 loss per share (vs AU$0.10 loss in FY 2021) Full year 2022 results: AU$0.16 loss per share (further deteriorated from AU$0.10 loss in FY 2021). Revenue: AU$3.87m (down 64% from FY 2021). Net loss: AU$14.3m (loss widened 82% from FY 2021). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings. Reported Earnings • Sep 02
Full year 2022 earnings released: AU$0.15 loss per share (vs AU$0.093 loss in FY 2021) Full year 2022 results: AU$0.15 loss per share (down from AU$0.093 loss in FY 2021). Revenue: AU$3.87m (down 64% from FY 2021). Net loss: AU$14.1m (loss widened 96% from FY 2021). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 19
Full year 2021 earnings released: AU$0.005 loss per share (vs AU$0.011 loss in FY 2020) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: AU$10.7m (up AU$9.00m from FY 2020). Net loss: AU$7.20m (loss narrowed 38% from FY 2020). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 24
First half 2021 earnings released: AU$0.001 loss per share (vs AU$0.006 loss in 1H 2020) The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: AU$6.91m (up 406% from 1H 2020). Net loss: AU$842.2k (loss narrowed 85% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. 